Cloud over US FDA inspection
Two US Congress members have expressed doubts over the quality of inspections conducted by the US Food and Drugs Administration (FDA) on Indian drug manufacturing facilities. Congressmen John Dingell and Bart Stupak have said the ongoing FDA-Ranbaxy row over alleged supply of "fraudulently approved and manufactured" medicines by Ranbaxy in the US should be seen in the larger context. Dingell is chairman of the energy and commerce committee, which oversees the FDA, while Stupak chairs its oversight and investigations subcommittee.